Spark Therapeutics, Inc. (ONCE) Given a $89.00 Price Target by BMO Capital Markets Analysts
BMO Capital Markets set a $89.00 price objective on Spark Therapeutics, Inc. (NASDAQ:ONCE) in a research note published on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages also recently commented on ONCE. Cantor Fitzgerald reiterated a buy rating on shares of Spark Therapeutics in a research report on Friday, August 25th. William Blair initiated coverage on Spark Therapeutics in a research report on Wednesday, June 28th. They set an outperform rating on the stock. ValuEngine upgraded Spark Therapeutics from a sell rating to a hold rating in a research report on Tuesday, June 20th. Chardan Capital upgraded Spark Therapeutics from a neutral rating to a buy rating and lifted their price objective for the stock from $60.00 to $100.00 in a research report on Tuesday, August 8th. Finally, BidaskClub upgraded Spark Therapeutics from a hold rating to a buy rating in a research report on Saturday, August 26th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seventeen have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $88.38.
Shares of Spark Therapeutics (ONCE) opened at 86.74 on Tuesday. The company’s market cap is $2.71 billion. Spark Therapeutics has a 1-year low of $35.07 and a 1-year high of $91.00. The firm has a 50-day moving average price of $85.90 and a 200-day moving average price of $85.90.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. During the same quarter in the previous year, the business posted ($1.04) EPS. The business’s quarterly revenue was up 14.7% compared to the same quarter last year. On average, equities analysts expect that Spark Therapeutics will post ($7.67) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/11/spark-therapeutics-inc-once-given-a-89-00-price-target-by-bmo-capital-markets-analysts.html.
In related news, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $86.16, for a total value of $430,800.00. Following the completion of the transaction, the insider now directly owns 215,000 shares in the company, valued at $18,524,400. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Hospital Of Philade Children’s sold 1,000,000 shares of Spark Therapeutics stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $84.63, for a total value of $84,630,000.00. Following the completion of the transaction, the director now owns 3,928,707 shares of the company’s stock, valued at $332,486,473.41. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,333,195 shares of company stock valued at $109,070,506. 7.30% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. lifted its holdings in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Spark Therapeutics during the 2nd quarter worth about $143,000. BNP Paribas Arbitrage SA lifted its holdings in Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the last quarter. Pacad Investment Ltd. lifted its holdings in Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after buying an additional 1,500 shares during the last quarter. Finally, Highbridge Capital Management LLC purchased a new stake in Spark Therapeutics during the 1st quarter worth about $227,000. Hedge funds and other institutional investors own 77.84% of the company’s stock.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.